The Food and Drug Administration announced traditional approval of Johnson & Johnson’s Darzalex Faspro with bortezomib, cyclophosphamide, and dexamethasone for newly diagnosed light chain amyloidosis. The FDA granted accelerated approval for this indication in 2021.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Zymeworks announces strategic initiative to optimize Ziihera cash flows
- Morning News Wrap-Up: Monday’s Biggest Stock Market Stories!
- Midday Fly By: Berkshire takes Alphabet stake, J&J buying cancer drug maker
- M&A News: Johnson & Johnson Stock (JNJ) Perks Up as it Lands $3B “Hold and Kill” Cancer Deal
- Johnson & Johnson to acquire Halda Therapeutics for $3.05B in cash